Resources
3 Results (showing 1 - 3)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 11/10/2020 (updated 4/3/2024)
In the context of the trends in Oregon SUD metrics and the increasing infectious complications related to IDU in other jurisdictions and their implications for HIV and HCV transmission, we sought to 1) describe statewide trends in IDU-related serious bacterial infections (SBI) hospitalizations overall and by SBI type and drug use diagnosis, 2) assess IDU-related SBI diagnoses among individuals living with HIV and HCV, and 3) and determine the annual costs of IDU-related SBI overall and by SBI type.
Posted 6/16/2020 (updated 3/28/2024)
The most effective therapy for people with opioid use disorder involves the use of Food and Drug Administration-approved medications—methadone, buprenorphine, and naltrexone. Despite evidence that this approach, known as medications for opioid use disorder, reduces relapse and saves lives, the vast majority of jails and prisons do not offer this treatment.
Posted 10/25/2022 (updated 3/27/2024)
Hepatitis C: State of Medicaid Access is a collaboration between the Center for Health Law and Policy Innovation of Harvard
Law School (CHLPI) and the National Viral Hepatitis Roundtable (NVHR). The project evaluates hepatitis C (HCV)
treatment restriction policies across state Medicaid programs, including all 50 states, the District of Columbia, and Puerto
Rico (referred to in this report as “states”). The goal of this project is to encourage states and empower advocates to work
toward improved access to curative HCV treatment across all Medicaid programs, in order to ensure that every Medicaid
enrollee who can benefit from this treatment is able to access it.